Evanston, United States
Aptinyx Inc. is a biopharmaceutical company aiming to address challenging disorders of the brain and nervous system, such as painful diabetic neuropathy, fibromyalgia, PTSD, and Parkinson’s cognitive impairment. Established in 2015, Aptinyx utilizes a platform for discovering proprietary compounds that operate through the modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
The company's latest funding round amounted to $5.60M, a grant investment received on 03 November 2022 from the National Institutes of Health.
By focusing on indications with a high unmet medical need, Aptinyx aims to advance its pipeline of novel clinical candidates swiftly. Based in the United States, their dedication extends to creating an engaging work environment, offering challenging work assignments, and providing competitive compensation and benefits for their employees.
For anyone interested in learning more about Aptinyx or exploring career opportunities, visiting their website at www.aptinyx.com or following them on Twitter at @Aptinyx is encouraged. With its innovative therapies and commitment to employee well-being, Aptinyx presents itself as a compelling prospect in the biopharma and biotechnology industries.
